◎ Sugi Atlas

Atlas / Drug / Imatinib

Imatinib

drug
On this page

Also known as GlamoxNSC-743414NSC-759854GLEEVECSTI-571IMATINIB MESYLATEGLIVECCGP-57148BSTI571CGP057148BST-1571IMATINIB (STI571)SID26755316SID29215405SID124892207SID124892208SID103905596Imatinib (STI-571)SID124892209

Summary

Imatinib (CHEMBL941) is an approved small-molecule tyrosine kinase inhibitor (ATC L01EA01) targeting DDR1, DDR2, and ABL1; indicated across 52 conditions including acute lymphoblastic leukemia and chronic myeloid leukemia; with CIViC clinical evidence for 203 variant-indication associations (e.g. FIP1L1::PDGFRA Fusion in myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EA01
  • Targets: 3 (DDR1, DDR2, ABL1)
  • Indications: 52 conditions
  • Clinical trials: 469
  • Precision-oncology evidence (CIViC): 203 variant–indication associations
  • Chemistry: 493.6 Da · C29H31N7O

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL941
NameImatinib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5291
ChEBICHEBI:45783
ATCL01EA01
Molecular formulaC29H31N7O
Molecular weight493.6
InChIKeyKTUFNOKKBVMGRW-UHFFFAOYSA-N

SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

IUPAC name: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide

ChEBI definition: A benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N3-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.

Pharmacological roles (ChEBI): tyrosine kinase inhibitor, antineoplastic agent, apoptosis inducer.

Also known as: Glamox, Imatinib, NSC-743414, NSC-759854, IMATINIB, GLEEVEC, STI-571, IMATINIB MESYLATE, GLIVEC, CGP-57148B, GLAMOX, STI571

Parent form; salt/anhydrous children: CHEMBL1642, CHEMBL2386595

Patent coverage: 28,675 distinct patent families (111,611 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 109,700 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
DDR1discoidin domain receptor tyrosine kinase 1Inhibition6.470.1%Q08345
DDR2discoidin domain receptor tyrosine kinase 2Inhibition6.170%Q16832
ABL1ABL proto-oncogene 1, non-receptor tyrosine kinaseInhibition6.71.2%P00519

Broader ChEMBL bioactivity targets: 85 (assay-derived). Sample: Homeodomain-interacting protein kinase 4, Nuclear receptor ROR-gamma, Prelamin-A/C, Solute carrier family 22 member 2, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Receptor tyrosine-protein kinase erbB-2, Thromboxane-A synthase, Tyrosine-protein kinase Fyn.

Bioactivity

ChEMBL activities: 407 potent at pChembl ≥ 5 of 430 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ERBB210.22IC500.06nMCHEMBL_ACT_24962908
EGFR9.96IC500.11nMCHEMBL_ACT_24962906
DDR19.15Kd0.7nMCHEMBL_ACT_2903445
DDR19.15Kd0.7nMCHEMBL_ACT_7568175
DDR19.1Kd0.79nMCHEMBL_ACT_18910095
ABL19Kd1nMCHEMBL_ACT_18910094
ABL18.96IC501.1nMCHEMBL_ACT_3186208
ABL18.96Kd1.1nMCHEMBL_ACT_7569852
ABL18.74Kd1.8nMCHEMBL_ACT_7569847
PDGFRA8.7IC502nMCHEMBL_ACT_13418824
ABL18.66Kd2.2nMCHEMBL_ACT_1651429
ABL18.6Kd2.5nMCHEMBL_ACT_7569842
ABL18.55IC502.79nMCHEMBL_ACT_24729011
PDGFRA8.55IC502.8nMCHEMBL_ACT_29279125
PDGFRA8.34IC504.6nMCHEMBL_ACT_18057971
ABL18.34IC504.6nMCHEMBL_ACT_29094610
ABL18.23Kd5.9nMCHEMBL_ACT_7569844
ABL28.22Kd6nMCHEMBL_ACT_6174264
BCR8.15Kd7nMCHEMBL_ACT_17884711
ABL18.08Kd8.3nMCHEMBL_ACT_7569840
ABL18.07Kd8.5nMCHEMBL_ACT_2895371
CSF1R8Kd10nMCHEMBL_ACT_18910092
ABL28Kd10nMCHEMBL_ACT_18910093
ABL28Kd10nMCHEMBL_ACT_22969941
ABL28Kd10nMCHEMBL_ACT_2895523
ABL28Kd10nMCHEMBL_ACT_7569854
P005207.97IC5010.8nMCHEMBL_ACT_3397785
CSF1R7.96Kd11nMCHEMBL_ACT_7569856
ABL17.92Kd12nMCHEMBL_ACT_2894829
KIT7.9Kd12.59nMCHEMBL_ACT_18910091

Target pathways

Aggregated over 3 target gene(s): DDR1, DDR2, ABL1.

Top Reactome pathways

54 total, by targets touching each:

PathwayTargetsGenes
Non-integrin membrane-ECM interactions2DDR1, DDR2
Hemostasis1ABL1
Developmental Biology1ABL1
Signal Transduction1ABL1
Cell Cycle1ABL1
Disease1ABL1
Innate Immune System1ABL1
Immune System1ABL1
Signaling by Rho GTPases1ABL1
RHO GTPase Effectors1ABL1
Fcgamma receptor (FCGR) dependent phagocytosis1ABL1
Regulation of actin dynamics for phagocytic cup formation1ABL1
Epigenetic regulation of gene expression1ABL1
Generic Transcription Pathway1ABL1
Signaling by ROBO receptors1ABL1
Axon guidance1ABL1
Role of ABL in ROBO-SLIT signaling1ABL1
Mitotic G1 phase and G1/S transition1ABL1
Myogenesis1ABL1
Infectious disease1ABL1
RHO GTPases Activate WASPs and WAVEs1ABL1
HDR through Single Strand Annealing (SSA)1ABL1
DNA Double-Strand Break Repair1ABL1
Homology Directed Repair1ABL1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks1ABL1
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)1ABL1
DNA Double Strand Break Response1ABL1
Cyclin D associated events in G11ABL1
G1 Phase1ABL1
Cell Cycle, Mitotic1ABL1

Dominant GO biological processes

GO termTargets
cell adhesion3
protein phosphorylation3
cell surface receptor protein tyrosine kinase signaling pathway2
regulation of extracellular matrix disassembly2
positive regulation of neuron projection development2
collagen-activated tyrosine kinase receptor signaling pathway2
protein autophosphorylation2
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction2
positive regulation of fibroblast proliferation2
positive regulation of ERK1 and ERK2 cascade2
cellular response to transforming growth factor beta stimulus2
regulation of cell growth1
regulation of cell-matrix adhesion1
embryo implantation1
lactation1

Indications & clinical

Indications

52 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
chronic myeloid leukemia3MONDO:0011996EFO:0000339
leukemia3MONDO:0005059EFO:0000565
neoplasm3MONDO:0005070EFO:0000616
sarcoma3MONDO:0005089EFO:0000691
pulmonary arterial hypertension3MONDO:0015924EFO:0001361
stroke disorder3MONDO:0005098EFO:0000712
myeloid leukemia3MONDO:0004643MONDO:0004643
pulmonary hypertension3MONDO:0005149MONDO:0005149
graft versus host disease3MONDO:0013730MONDO:0013730
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
gastrointestinal stromal tumor3MONDO:0011719MONDO:0011719
pneumonia3MONDO:0005249EFO:0003106
influenza3MONDO:0005812EFO:0007328
acute myeloid leukemia2MONDO:0018874EFO:0000222
fibromatosis2MONDO:0005031EFO:0000497
gastric adenocarcinoma2MONDO:0005036EFO:0000503
glioblastoma2MONDO:0018177EFO:0000519
rheumatoid arthritis2MONDO:0008383EFO:0000685
systemic sclerosis2MONDO:0005100EFO:0000717
melanoma2MONDO:0005105EFO:0000756
metastatic melanoma2MONDO:0005191EFO:0002617
gastric neoplasm2MONDO:0021085EFO:0003897
colonic neoplasm2MONDO:0005401EFO:0004288
Plasmodium falciparum malaria2MONDO:0005920EFO:0007444
thyroid gland papillary carcinoma2MONDO:0005075EFO:0000641
hypereosinophilic syndrome2MONDO:0015691EFO:1001467
breast neoplasm2MONDO:0021100MONDO:0007254
lung neoplasm2MONDO:0021117MONDO:0008903
spinal cord injury2MONDO:0043797EFO:1001919
desmoid tumor2MONDO:0007608EFO:0009907
chordoma2MONDO:0008978MONDO:0008978
tuberculosis2MONDO:0018076MONDO:0018076
lymphoid leukemia2MONDO:0005402EFO:0004289
clear cell renal carcinoma1MONDO:0005005EFO:0000349
colorectal adenocarcinoma1MONDO:0005008EFO:0000365
fibrosarcoma1MONDO:0005164EFO:0002087
anaplastic large cell lymphoma1MONDO:0020325EFO:0003032
seasonal allergic rhinitis1MONDO:0005324EFO:0003956
acute lung injury1MONDO:0015796EFO:0004610
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
desmoplastic small round cell tumor1MONDO:0019373EFO:1000895
thymic carcinoma1MONDO:0006451EFO:1000576
hematopoietic and lymphoid system neoplasm1MONDO:0002334MONDO:0044881
cirrhosis of liver1MONDO:0005155EFO:0001422
malignant pancreatic neoplasm1MONDO:0009831EFO:1000359
colorectal neoplasm1MONDO:0005335MONDO:0005575
head and neck squamous cell carcinoma0MONDO:0010150EFO:0000181
head and neck cancer0MONDO:0005627EFO:0006859

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 469.

Phase distribution

PhaseTrials
PHASE2239
PHASE372
PHASE161
PHASE1/PHASE244
Not specified29
PHASE418
PHASE2/PHASE33
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03844360PHASE4RECRUITINGDose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
NCT04877522PHASE4RECRUITINGAsciminib Roll-over Study
NCT05367765PHASE4NOT_YET_RECRUITINGA Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT00081926PHASE4COMPLETEDGleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT00171899PHASE4COMPLETEDStudy Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
NCT00171977PHASE4COMPLETEDPost-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
NCT00372476PHASE4COMPLETEDEfficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
NCT00390897PHASE4COMPLETEDGlivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
NCT00510354PHASE4COMPLETEDTreatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
NCT01297777PHASE4COMPLETEDImatinib in KIT-negative Systemic Mastocytosis
NCT01491763PHASE4UNKNOWNChemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE
NCT01578213PHASE4COMPLETEDValidation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients
NCT01742299PHASE4COMPLETEDStudy to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
NCT02317159PHASE4UNKNOWNEfficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
NCT02602314PHASE4UNKNOWNSustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
NCT02894645PHASE4UNKNOWNMalaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
NCT05071482PHASE4TERMINATEDFlumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
NCT05220280PHASE4UNKNOWNSOLIDARITY Finland Plus Long-COVID
NCT02413736PHASE3ACTIVE_NOT_RECRUITINGThree Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
NCT02735707PHASE3RECRUITINGRandomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT03007147PHASE3ACTIVE_NOT_RECRUITINGImatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03589326PHASE3ACTIVE_NOT_RECRUITINGA Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03722420PHASE3ACTIVE_NOT_RECRUITINGRandomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
NCT04307576PHASE3RECRUITINGA Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04722848PHASE3ACTIVE_NOT_RECRUITINGSequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04971226PHASE3ACTIVE_NOT_RECRUITINGA Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT05970900PHASE3NOT_YET_RECRUITINGPreoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST
NCT06682169PHASE3RECRUITINGEvaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT07530367PHASE3NOT_YET_RECRUITINGA Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis
NCT07585266PHASE3NOT_YET_RECRUITINGA Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
NCT00002514PHASE3COMPLETEDStem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
NCT00006343PHASE3COMPLETEDSTI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
NCT00009906PHASE3TERMINATEDComparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
NCT00022737PHASE3COMPLETEDCombination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
NCT00041197PHASE3COMPLETEDImatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
NCT00050531PHASE3COMPLETEDHigh-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
NCT00055874PHASE3COMPLETEDImatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT00103168PHASE3COMPLETEDImatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
NCT00116935PHASE3COMPLETEDStudy Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
NCT00124748PHASE3TERMINATEDEfficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

Clinical evidence (CIViC)

Variant × indication × effect (203 predictive associations from 263 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
FIP1L1::PDGFRA FusionMyeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1Sensitivity/ResponseImatinibCIViC AEID1445 +2
KIT Exon 11 MutationGastrointestinal Stromal TumorSensitivity/ResponseImatinibCIViC AEID654 +2
BCR::ABL1 FusionChronic Myeloid LeukemiaSensitivity/ResponseImatinibCIViC AEID260 +1
KIT Exon 9 MutationGastrointestinal Stromal TumorSensitivity/ResponseImatinibCIViC AEID1221 +1
PDGFRB FusionMyeloproliferative NeoplasmSensitivity/ResponseImatinibCIViC AEID11272 +1
BCR::ABL1 FusionAcute Myeloid LeukemiaSensitivity/ResponseImatinibCIViC AEID259
COL1A1::PDGFB FusionDermatofibrosarcoma ProtuberansSensitivity/ResponseImatinibCIViC AEID11271
FIP1L1::PDGFRA FusionMyeloproliferative NeoplasmSensitivity/ResponseImatinibCIViC AEID11273
KIT MutationGastrointestinal Stromal TumorSensitivity/ResponseImatinibCIViC AEID11282
PDGFRA D842VGastrointestinal Stromal TumorSensitivity/ResponseImatinibCIViC AEID11545
PDGFRA MutationGastrointestinal Stromal TumorSensitivity/ResponseImatinibCIViC BEID11331 +1
BCL2L11 Deletion PolymorphismChronic Myeloid LeukemiaSensitivity/ResponseImatinibCIViC BEID9701
CTNNB1 S45FDesmoid TumorSensitivity/ResponseImatinibCIViC BEID11018
ETV6::ABL1 FusionMyeloid NeoplasmSensitivity/ResponseImatinib + Dasatinib + NilotinibCIViC BEID11326
IKZF1 DeletionB-lymphoblastic Leukemia/lymphomaSensitivity/ResponseMethotrexate + Daunorubicin + Cytarabine + Fludarabine + ImatinibCIViC BEID7366
KIT EXPRESSIONGastrointestinal Stromal TumorSensitivity/ResponseImatinibCIViC BEID2480
KIT Exon 11 MutationMelanomaSensitivity/ResponseImatinibCIViC BEID58
KIT MutationMelanomaSensitivity/ResponseImatinibCIViC BEID1222
KIT Y503_F504insAYGastrointestinal Stromal TumorSensitivity/ResponseImatinibCIViC BEID2394
NOT KIT D816VSystemic MastocytosisSensitivity/ResponseImatinibCIViC BEID11158
KIT Exon 11 W557del/K558delGastrointestinal Stromal TumorReduced SensitivityImatinibCIViC BEID12935
KIT Exon 9 MutationGastrointestinal Stromal TumorReduced SensitivityImatinibCIViC BEID2477
BCR::ABL1 Fusion AND ABL1 T315IChronic Myeloid LeukemiaResistanceImatinibCIViC BEID234 +4
KIT Q694KGastrointestinal Stromal TumorResistanceImatinibCIViC BEID2498 +4
KIT S692LGastrointestinal Stromal TumorResistanceImatinibCIViC BEID2493 +4
PDGFRA D842VGastrointestinal Stromal TumorResistanceImatinibCIViC BEID15 +4
KIT S501_A502INSAYGastrointestinal Stromal TumorResistanceImatinibCIViC BEID2855 +3
KIT T661IGastrointestinal Stromal TumorResistanceImatinibCIViC BEID2491 +3
BCL2L11 Deletion PolymorphismChronic Myeloid LeukemiaResistanceImatinibCIViC BEID1280
KIT AmplificationMucosal MelanomaResistanceImatinibCIViC BEID1466

+173 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 39 clinical and 212 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

129 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
AfatinibChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
CABOZANTINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
DASATINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
ENTRECTINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
ERLOTINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
FEDRATINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
GefitinibChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
IbrutinibChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
LapatinibChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
PAZOPANIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
PONATINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
QUIZARTINIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
REGORAFENIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
RuxolitinibChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
SORAFENIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
TirbanibulinChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
TOVORAFENIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
VANDETANIBChEMBL + PubChemPhase 4 (approved)ABL1, DDR1, DDR2
AXITINIBChEMBLPhase 4 (approved)ABL1, DDR1, DDR2
BOSUTINIBChEMBLPhase 4 (approved)ABL1, DDR1, DDR2
LENVATINIBChEMBLPhase 4 (approved)ABL1, DDR1, DDR2
NILOTINIBChEMBLPhase 4 (approved)ABL1, DDR1, DDR2
NINTEDANIBChEMBLPhase 4 (approved)ABL1, DDR1, DDR2
SUNITINIBChEMBLPhase 4 (approved)ABL1, DDR1, DDR2
TIVOZANIBChEMBLPhase 4 (approved)ABL1, DDR1, DDR2
CEDIRANIBChEMBLPhase 3ABL1, DDR1, DDR2
DOVITINIBChEMBLPhase 3ABL1, DDR1, DDR2
LESTAURTINIBChEMBLPhase 3ABL1, DDR1, DDR2
LINIFANIBChEMBLPhase 3ABL1, DDR1, DDR2
MASITINIBChEMBLPhase 3ABL1, DDR1, DDR2
SARACATINIBChEMBLPhase 3ABL1, DDR1, DDR2
TESEVATINIBChEMBLPhase 3ABL1, DDR1, DDR2
AEE-788ChEMBLPhase 2ABL1, DDR1, DDR2
BAFETINIBChEMBLPhase 2ABL1, DDR1, DDR2
BMS-777607ChEMBLPhase 2ABL1, DDR1, DDR2
CEP-32496ChEMBLPhase 2ABL1, DDR1, DDR2
DANUSERTIBChEMBLPhase 2ABL1, DDR1, DDR2
DEFOSBARASERTIBChEMBLPhase 2ABL1, DDR1, DDR2
DORAMAPIMODChEMBLPhase 2ABL1, DDR1, DDR2
ENMD-2076ChEMBLPhase 2ABL1, DDR1, DDR2
FORETINIBChEMBLPhase 2ABL1, DDR1, DDR2
GLESATINIBChEMBLPhase 2ABL1, DDR1, DDR2
GOLVATINIBChEMBLPhase 2ABL1, DDR1, DDR2
MILCICLIBChEMBLPhase 2ABL1, DDR1, DDR2
OSI-632ChEMBLPhase 2ABL1, DDR1, DDR2
PEXMETINIBChEMBLPhase 2ABL1, DDR1, DDR2
R-406ChEMBLPhase 2ABL1, DDR1, DDR2
RAF-265ChEMBLPhase 2ABL1, DDR1, DDR2
REBASTINIBChEMBLPhase 2ABL1, DDR1, DDR2
TOZASERTIBChEMBLPhase 2ABL1, DDR1, DDR2
BinimetinibPubChemApprovedABL1, DDR1, DDR2
dacomitinibPubChemApprovedABL1, DDR1, DDR2
FostamatinibPubChemApprovedABL1, DDR1, DDR2
IdelalisibPubChemApprovedABL1, DDR1, DDR2
SelumetinibPubChemApprovedABL1, DDR1, DDR2
TrametinibPubChemApprovedABL1, DDR1, DDR2
DabrafenibChEMBL + PubChemPhase 4 (approved)ABL1, DDR1
MIDOSTAURINChEMBLPhase 4 (approved)ABL1, DDR1
BRIVANIBChEMBLPhase 3ABL1, DDR1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot